Redhill Biopharma Stock Buy Hold or Sell Recommendation
| RDHL Stock | USD 7.96 0.05 0.63% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Redhill Biopharma is 'Strong Sell'. The recommendation algorithm takes into account all of Redhill Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Redhill Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide. Note, we conduct extensive research on individual companies such as Redhill and provide practical buy, sell, or hold advice based on investors' constraints. Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Redhill |
Execute Redhill Biopharma Buy or Sell Advice
The Redhill recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Redhill Biopharma. Macroaxis does not own or have any residual interests in Redhill Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Redhill Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Redhill Biopharma Trading Alerts and Improvement Suggestions
| Redhill Biopharma had very high historical volatility over the last 90 days | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Latest headline from investing.com: GT Biopharma faces Nasdaq delisting over equity shortfall |
Redhill Biopharma Returns Distribution Density
The distribution of Redhill Biopharma's historical returns is an attempt to chart the uncertainty of Redhill Biopharma's future price movements. The chart of the probability distribution of Redhill Biopharma daily returns describes the distribution of returns around its average expected value. We use Redhill Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Redhill Biopharma returns is essential to provide solid investment advice for Redhill Biopharma.
| Mean Return | 0.19 | Value At Risk | -6.57 | Potential Upside | 9.81 | Standard Deviation | 4.90 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Redhill Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Redhill Stock Institutional Investors
| Shares | Ifp Advisors, Llc | 2024-06-30 | 7.0 | We Are One Seven, Llc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Aspire Private Capital, Llc | 2024-06-30 | 0.0 | F.l.putnam Investment Management | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Gagnon Securities Llc | 2024-09-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 1.3 M | Ubs Group Ag | 2024-06-30 | 142.4 K | Jane Street Group Llc | 2024-06-30 | 47.1 K |
Redhill Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 18K | 272K | 179K | (9.5M) | (14.4M) | (13.7M) | |
| Free Cash Flow | (41.0M) | (102.4M) | (65.2M) | (29.4M) | (35.8M) | (37.6M) | |
| Other Non Cash Items | (347K) | 6.0M | 5.4M | 20.6M | (47.8M) | (45.4M) | |
| Capital Expenditures | 203K | 53.8M | 115K | 198K | 11K | 10.5K | |
| Net Income | (42.3M) | (76.2M) | (97.7M) | (71.7M) | 23.9M | 25.1M | |
| End Period Cash Flow | 29.0M | 29.3M | 29.5M | 20.0M | 5.6M | 5.3M | |
| Depreciation | 1.2M | 8.7M | 18.1M | 8.2M | 2.0M | 3.3M | |
| Investments | 5.2M | (35.6M) | (8.0M) | 8.3M | 4K | 4.2K | |
| Change To Netincome | 2.8M | 2.7M | 11.2M | 24.6M | 28.3M | 29.7M | |
| Change To Inventory | (1.1M) | (4.6M) | (8.3M) | 3.8M | 2.4M | 2.5M |
Redhill Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Redhill Biopharma or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Redhill Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Redhill stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.10 | |
β | Beta against Dow Jones | 0.70 | |
σ | Overall volatility | 4.78 | |
Ir | Information ratio | 0.01 |
Redhill Biopharma Volatility Alert
Redhill Biopharma shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Redhill Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Redhill Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Redhill Biopharma Fundamentals Vs Peers
Comparing Redhill Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Redhill Biopharma's direct or indirect competition across all of the common fundamentals between Redhill Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Redhill Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Redhill Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Redhill Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Redhill Biopharma to competition |
| Fundamentals | Redhill Biopharma | Peer Average |
| Return On Equity | -17.09 | -0.31 |
| Return On Asset | -0.45 | -0.14 |
| Operating Margin | (3.28) % | (5.51) % |
| Current Valuation | 3.47 M | 16.62 B |
| Shares Outstanding | 1.28 M | 571.82 M |
| Shares Owned By Institutions | 5.90 % | 39.21 % |
| Number Of Shares Shorted | 6.83 K | 4.71 M |
| Price To Earning | (3.67) X | 28.72 X |
| Price To Book | 167.10 X | 9.51 X |
| Price To Sales | 2.75 X | 11.42 X |
| Revenue | 6.51 M | 9.43 B |
| Gross Profit | 45.25 M | 27.38 B |
| EBITDA | 26.31 M | 3.9 B |
| Net Income | 23.92 M | 570.98 M |
| Cash And Equivalents | 28.86 M | 2.7 B |
| Cash Per Share | 0.55 X | 5.01 X |
| Total Debt | 1.17 M | 5.32 B |
| Debt To Equity | 9.89 % | 48.70 % |
| Current Ratio | 0.98 X | 2.16 X |
| Book Value Per Share | 0.05 X | 1.93 K |
| Cash Flow From Operations | (35.82 M) | 971.22 M |
| Short Ratio | 0.48 X | 4.00 X |
| Earnings Per Share | (302.63) X | 3.12 X |
| Target Price | 19000.0 | |
| Number Of Employees | 53 | 18.84 K |
| Beta | 3.67 | -0.15 |
| Market Capitalization | 10.19 M | 19.03 B |
| Total Asset | 23.05 M | 29.47 B |
| Retained Earnings | (407.74 M) | 9.33 B |
| Working Capital | (3.1 M) | 1.48 B |
| Current Asset | 60.51 M | 9.34 B |
| Current Liabilities | 5.51 M | 7.9 B |
| Net Asset | 23.05 M |
Redhill Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Redhill . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Redhill Biopharma Buy or Sell Advice
When is the right time to buy or sell Redhill Biopharma? Buying financial instruments such as Redhill Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Redhill Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Debt ETFs Thematic Idea Now
Broad Debt ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Debt ETFs theme has 230 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Debt ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Redhill Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.